Charles River Laboratories International (CRL) Stock Overview
Charles River Laboratories International, Inc. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CRL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Charles River Laboratories International, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$159.40 |
| 52 Week High | US$254.15 |
| 52 Week Low | US$91.86 |
| Beta | 1.5 |
| 1 Month Change | 6.66% |
| 3 Month Change | 49.53% |
| 1 Year Change | -26.27% |
| 3 Year Change | -27.46% |
| 5 Year Change | -18.78% |
| Change since IPO | 624.55% |
Recent News & Updates
There's No Escaping Charles River Laboratories International, Inc.'s (NYSE:CRL) Muted Revenues Despite A 25% Share Price Rise
May 24
We Think Charles River Laboratories International, Inc.'s (NYSE:CRL) CEO Compensation Package Needs To Be Put Under A Microscope
May 14Recent updates
There's No Escaping Charles River Laboratories International, Inc.'s (NYSE:CRL) Muted Revenues Despite A 25% Share Price Rise
May 24We Think Charles River Laboratories International, Inc.'s (NYSE:CRL) CEO Compensation Package Needs To Be Put Under A Microscope
May 14Charles River Faces Significant Regulatory And Macro Pressures
Apr 11Revenues Working Against Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Following 30% Dive
Apr 09Should You Investigate Charles River Laboratories International, Inc. (NYSE:CRL) At US$171?
Mar 13Charles River Laboratories International's (NYSE:CRL) Soft Earnings Are Actually Better Than They Appear
Feb 26Charles River Laboratories International, Inc. (NYSE:CRL) Shares Could Be 39% Below Their Intrinsic Value Estimate
Feb 10Charles River Laboratories: Retained Earnings, ROE, And Debt Management Will Shape Its Future Amid Weak Demand
Feb 01We Think Charles River Laboratories International (NYSE:CRL) Is Taking Some Risk With Its Debt
Jan 26Charles River Labs: Near A Fundamental Trough, Growth Should Reignite Again
Jan 17What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You
Jan 10Is There Now An Opportunity In Charles River Laboratories International, Inc. (NYSE:CRL)?
Dec 11Charles River Laboratories: Not The Right Time To Own At This Point In The Cycle
Nov 19Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 26What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You
Oct 11Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching
Sep 10
Cost Efficiency And Digital Strategy Propel Earnings Amidst Pharma Industry Challenges
Initiatives for cost efficiency and operational restructuring, including staff reductions, aim to boost net margins through significant annualized savings.US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results
Aug 10Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Aug 10Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt
Jul 26Charles River Laboratories: Fair Valuation Against Fundamentals
May 31Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Shareholder Returns
| CRL | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 1.5% | 0.6% | -0.5% |
| 1Y | -26.3% | -18.5% | 11.7% |
Return vs Industry: CRL underperformed the US Life Sciences industry which returned -18.5% over the past year.
Return vs Market: CRL underperformed the US Market which returned 11.7% over the past year.
Price Volatility
| CRL volatility | |
|---|---|
| CRL Average Weekly Movement | 7.3% |
| Life Sciences Industry Average Movement | 8.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CRL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CRL's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | 19,400 | Jim Foster | www.criver.com |
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.
Charles River Laboratories International, Inc. Fundamentals Summary
| CRL fundamental statistics | |
|---|---|
| Market cap | US$7.83b |
| Earnings (TTM) | -US$31.56m |
| Revenue (TTM) | US$4.02b |
Is CRL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRL income statement (TTM) | |
|---|---|
| Revenue | US$4.02b |
| Cost of Revenue | US$2.63b |
| Gross Profit | US$1.40b |
| Other Expenses | US$1.43b |
| Earnings | -US$31.56m |
Last Reported Earnings
Mar 29, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 34.69% |
| Net Profit Margin | -0.78% |
| Debt/Equity Ratio | 76.7% |
How did CRL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/13 02:11 |
| End of Day Share Price | 2025/07/11 00:00 |
| Earnings | 2025/03/29 |
| Annual Earnings | 2024/12/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Charles River Laboratories International, Inc. is covered by 43 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Gregory Bolan | Avondale Partners |
| Eric Coldwell | Baird |